PGAP3 and gastric cancer: Kaplan–Meier survival analysis in 343 GC patients unravelled that the proportion of total survival is 35%, and overexpression of PGAP3 or ERBB2 has significant poor survival proportion compared with low expression in GC patients, respectively (32.3% and 44.6%, *p = 0.011; 27.4% and 40.6%, **p = 0.007) (Tables S7 and S8, Figure 3B).